JP2018530315A - 疼痛の治療を目的とする組成物及び方法 - Google Patents

疼痛の治療を目的とする組成物及び方法 Download PDF

Info

Publication number
JP2018530315A
JP2018530315A JP2018510813A JP2018510813A JP2018530315A JP 2018530315 A JP2018530315 A JP 2018530315A JP 2018510813 A JP2018510813 A JP 2018510813A JP 2018510813 A JP2018510813 A JP 2018510813A JP 2018530315 A JP2018530315 A JP 2018530315A
Authority
JP
Japan
Prior art keywords
fusion protein
toxin
domain
btx
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018510813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018530315A5 (enExample
Inventor
アール． ジョン コリアー
アール． ジョン コリアー
アイザック チウ
アイザック チウ
ブラッドリー エル． ペンテリュート
ブラッドリー エル． ペンテリュート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2018530315A publication Critical patent/JP2018530315A/ja
Publication of JP2018530315A5 publication Critical patent/JP2018530315A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018510813A 2015-08-27 2016-08-26 疼痛の治療を目的とする組成物及び方法 Pending JP2018530315A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562210610P 2015-08-27 2015-08-27
US62/210,610 2015-08-27
PCT/US2016/049099 WO2017035507A1 (en) 2015-08-27 2016-08-26 Compositions and methods for treatment of pain

Publications (2)

Publication Number Publication Date
JP2018530315A true JP2018530315A (ja) 2018-10-18
JP2018530315A5 JP2018530315A5 (enExample) 2019-10-03

Family

ID=58101095

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018510813A Pending JP2018530315A (ja) 2015-08-27 2016-08-26 疼痛の治療を目的とする組成物及び方法
JP2018511085A Pending JP2018525021A (ja) 2015-08-27 2016-08-26 疼痛の治療を目的とする組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018511085A Pending JP2018525021A (ja) 2015-08-27 2016-08-26 疼痛の治療を目的とする組成物及び方法

Country Status (11)

Country Link
US (4) US11753633B2 (enExample)
EP (2) EP3341391A4 (enExample)
JP (2) JP2018530315A (enExample)
KR (2) KR20180070563A (enExample)
CN (2) CN108350039A (enExample)
AU (2) AU2016312685A1 (enExample)
BR (2) BR112018003782A2 (enExample)
CA (2) CA2994560A1 (enExample)
EA (1) EA201890587A1 (enExample)
MX (1) MX2018002183A (enExample)
WO (2) WO2017035508A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022511885A (ja) * 2018-12-06 2022-02-01 エムジェイセル バイオ カンパニー リミテッド ヒト抗ａｎｔｘｒキメラ抗原受容体及びその用途
JP2024510786A (ja) * 2021-03-26 2024-03-11 イプセン バイオファーム リミテッド 外来性の活性化ループを含むクロストリジウム神経毒素

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220354962A1 (en) * 2015-05-12 2022-11-10 The Trustees Of The University Of Pennsylvania Rapid production of bispecific antibodies from off-the-shelf iggs with high yield and purity
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
MX2018002183A (es) 2015-08-27 2018-05-28 Harvard College Composiciones y metodos para tratamiento del dolor.
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3481852B1 (en) * 2016-07-08 2022-12-07 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
CN112105379A (zh) * 2017-09-29 2020-12-18 儿童医学中心公司 神经毒素样毒素及其用途
BR112020006827A2 (pt) 2018-01-29 2020-10-06 Ipsen Biopharm Limited neurotoxinas botulínicas clivando snare não neuronal
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
CA3101481A1 (en) * 2018-05-30 2019-12-05 The Governing Council Of The University Of Toronto Methods and kits for identifying a protein associated with receptor-ligand interactions
US20210380700A1 (en) * 2018-07-06 2021-12-09 Abmax Biopharmaceuticals De-adcc/cdc functions of antibodies and their applications
MX2021001181A (es) 2018-07-31 2021-04-19 Snoretox Pty Ltd Neurotoxinas tetanicas pegiladas y tratamiento de la hipotonia.
EP4093434A4 (en) * 2020-01-21 2024-06-26 Trustees of Dartmouth College Immunologically optimized botulinum toxin light chain variants
JP2023522534A (ja) * 2020-02-03 2023-05-31 プレマス バイオテック プライベート リミテッド 発現が困難なタンパク質を発現させるための、組換え発現プラットフォーム、構築物、および方法
US20230165812A1 (en) * 2020-02-27 2023-06-01 President And Fellows Of Harvard College Nociceptor neurons control cancer immunosurveillance
KR102728382B1 (ko) * 2022-10-12 2024-11-14 주식회사 알케미어 보툴리눔 독소의 경쇄 변이체
CN122520722A (zh) * 2024-03-26 2026-08-07 广州锡滔生物医药科技有限公司 一种多肽及其应用
WO2026076425A1 (en) 2024-10-04 2026-04-09 Biodrive, Inc. Oral biodelivery platform
CN122080238B (zh) * 2026-04-21 2026-07-31 成都锐翼生物科技有限公司 rBoNT重组蛋白及其前体及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130336974A1 (en) * 2011-01-10 2013-12-19 President And Fellows Of Harvard College Method for delivering agents into cells using bacterial toxins
US20140056870A1 (en) * 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
JP2014516526A (ja) * 2011-05-16 2014-07-17 シンタクシン リミテッド 治療用融合タンパク質

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
JP2000503004A (ja) 1995-12-13 2000-03-14 プレジデント アンド フェロウズ オブ ハーバード カレッジ 化合物を細胞に輸送するための毒素ペプチドおよび／またはアフィニティハンドルの使用
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
US6767896B1 (en) 1999-01-29 2004-07-27 Cognetix, Inc. Conotoxin peptides
EP2267008B1 (en) 1999-08-25 2014-07-02 Allergan, Inc. Activatable recombinant neurotoxins
EP1214340B1 (en) 1999-09-24 2004-11-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors
JP2003533178A (ja) 1999-12-30 2003-11-11 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション Ｏ−スーパーファミリー・コノトキシンペプチド
JP2006507800A (ja) * 2002-06-07 2006-03-09 ラージ・スケール・バイオロジー・コーポレイション 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
EP1858546A4 (en) 2005-03-04 2009-03-04 Biorexis Pharmaceutical Corp MODIFIED TRANSFERRINFUSION PROTEINS
DK2154151T3 (da) 2005-09-19 2011-09-05 Allergan Inc Clostridiumtoksinaktiverbare clostridiumtoksiner
JP2009514545A (ja) 2005-11-08 2009-04-09 アテリス ラボラトリーズ μ−コノトキシンぺプチドおよびμ−コノトキシンぺプチドの局所麻酔薬としての使用
CA2601537A1 (en) 2006-03-14 2007-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
WO2008008805A2 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
AU2007272515B2 (en) 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
US9284358B2 (en) 2006-07-18 2016-03-15 University Of Utah Research Foundation Conotoxin peptides
CA2865243A1 (en) 2012-02-23 2013-08-29 President And Fellows Of Harvard College Modified microbial toxin receptor for delivering agents into cells
WO2013177231A1 (en) 2012-05-21 2013-11-28 Massachusetts Institute Of Technology Translocation of non-natural chemical entities through anthrax protective antigen pore
WO2014088928A1 (en) 2012-12-03 2014-06-12 President And Fellows Of Harvard College Methods for making targeted protein toxins by sortase-mediated protein ligation
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
MX2018002183A (es) 2015-08-27 2018-05-28 Harvard College Composiciones y metodos para tratamiento del dolor.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130336974A1 (en) * 2011-01-10 2013-12-19 President And Fellows Of Harvard College Method for delivering agents into cells using bacterial toxins
JP2014516526A (ja) * 2011-05-16 2014-07-17 シンタクシン リミテッド 治療用融合タンパク質
US20140056870A1 (en) * 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022511885A (ja) * 2018-12-06 2022-02-01 エムジェイセル バイオ カンパニー リミテッド ヒト抗ａｎｔｘｒキメラ抗原受容体及びその用途
JP7209091B2 (ja) 2018-12-06 2023-01-19 エムジェイセル バイオ カンパニー リミテッド ヒト抗ａｎｔｘｒキメラ抗原受容体及びその用途
US12331087B2 (en) 2018-12-06 2025-06-17 Mjcell Bio Co., Ltd. Human anti-ANTXR chimeric antigen receptor and use thereof
JP2024510786A (ja) * 2021-03-26 2024-03-11 イプセン バイオファーム リミテッド 外来性の活性化ループを含むクロストリジウム神経毒素

Also Published As

Publication number Publication date
AU2016312685A1 (en) 2018-03-01
EP3341392A4 (en) 2019-01-23
US20180251740A1 (en) 2018-09-06
EP3341392A1 (en) 2018-07-04
US11104892B2 (en) 2021-08-31
AU2016310521A1 (en) 2018-03-01
WO2017035507A1 (en) 2017-03-02
JP2018525021A (ja) 2018-09-06
EP3341391A4 (en) 2019-03-06
US10704035B2 (en) 2020-07-07
CN108350039A (zh) 2018-07-31
EA201890587A1 (ru) 2018-09-28
US11753633B2 (en) 2023-09-12
CA2994560A1 (en) 2017-03-02
EP3341391A1 (en) 2018-07-04
US20180244731A1 (en) 2018-08-30
CN108602861A (zh) 2018-09-28
BR112018003782A2 (pt) 2018-09-25
KR20180050679A (ko) 2018-05-15
CA2994729A1 (en) 2017-03-02
MX2018002183A (es) 2018-05-28
WO2017035508A1 (en) 2017-03-02
US20220033795A1 (en) 2022-02-03
BR112018003794A2 (pt) 2018-09-25
US20200362325A1 (en) 2020-11-19
KR20180070563A (ko) 2018-06-26

Similar Documents

Publication Publication Date Title
US11104892B2 (en) Compositions and methods for treatment of pain
JP7402916B2 (ja) 新規ボツリヌスニューロトキシンおよびその誘導体
US12098169B2 (en) Enterococcus faecium neurotoxin (BoNT/EN) and derivatives thereof
US12589139B2 (en) Clostridial neurotoxins comprising an exogenous activation loop
ES2873479T3 (es) Neurotoxinas catiónicas
MXPA00011148A (es) Proteina hibrida para la inhibicion de la desgranulacion de los mastocitos y su utilizacion..
AU2006207726A1 (en) Recombinant expression of proteins in a disulfide-bridged, two-chain form
JP2018525021A5 (enExample)
CN107438670A (zh) 嵌合多肽
US20240158773A1 (en) Engineered botulinum neurotoxin a protease domain with improved efficacy
JP2020039349A (ja) かゆみの抑制
CN120282979A (zh) 包含活化内体蛋白酶裂解位点的梭菌神经毒素
HK1261168A1 (zh) 用於治疗疼痛的组合物和方法
RU2801120C2 (ru) Меченные сортазой нейротоксины клостридий
EA047022B1 (ru) Клостридиальные нейротоксины, содержащие экзогенную петлю активации

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180529

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190823

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200720

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210315